Early clinical research
WaKING — Wnt + checkpoint inhibition in gastric cancer
WaKING: Wnt and checKpoint INhibition in Gastric Cancer
- Phase
- Phase I/II
- Recruitment
- Active, not recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT04166721
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Researchers are testing immunotherapy combined with another cell-signaling pathway in gastric cancer.
Why promising? Combining Wnt signaling with immune microenvironment opens an early clinical path in gastric cancer.
What is not proven? No phase III superiority; does not replace standard CLDN18.2/HER2 paths.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Early phase (I/II); enrollment closed.
Cancer / population: Gastric / esophageal — İleri mide kanseri (protokol ölçütleri)
Intervention: Wnt yolu + immün kontrol noktası kombinasyonu (protokol)
Primary endpoint: Güvenlik / erken etkinlik
Limitations: Erken faz; sonuç olgunluğu kontrol edilmeli.